Researchers used Artificial Intelligence to treat Cancer : Clinical Research
Researchers from National University of Singapore (NUS) have used the power of artificial intelligence (AI) to successfully treat a patient with cancer in advanced stage and completely stopping disease progression.
In this clinical research study, researchers administered a patient with metastatic castration-resistant prostate cancer (MCRPC) a new drug combination consisting of the investigational drug ZEN-3694 and approved prostate cancer drug Enzalutamide.
The research team successfully utilized the platform, called CURATE.AI, to continuously find the optimal doses of each drug to result in a long-lasting response, allowing the patient to resume a completely active and normal lifestyle.
To overcome the challenges faced in conventional combination therapy, the team of researchers developed the CURATE.AI platform. It uses the clinical data of the patient like their drug doses and corresponding changes to sizes of tumor or levels of cancer biomarkers in blood - to calibrate her or his unique response to treatment.
The researchers then used this calibration to create a personalized CURATE.AI profile, or map, that identifies the drug doses which enable the best possible treatment outcome at any given point in time.
In CT imaging researchers found that the patient’s lesions showed halted disease progression due to CURATE.AI-guided combination therapy of both ZEN-3694 and enzalutamide.
According to Researchers using CURATE.AI to dynamically modify drug doses and to treat successfully a metastatic cancer patient represents a landmark breakthrough for the use of Artificial Intelligence to truly personalize patient care.
Further they said that this advance is expected to dramatically improve response rates for all combination therapies that are related to oncology and all other diseases.
The CURATE.AI researchers are broadly expanding the platform for the prevention of transplant rejection, pediatric and adult cancers, diabetes management, infectious diseases, cardiovascular medicine and many other applications.
This article is edited and restructured one. Please check complete details below
Original Study DOI: 10.1002/adtp.201800104
Hello Visitors. Welcome to this blog .For any queries related to pharma please feel free to contact us at on our mail pharmastuff.blogspot.com@gmail.com
1 comments:
Click here for commentsArtificial Intelligence may now really customise patient treatment, dynamically change medicine dosages and successfully treat a metastatic cancer patient. It uses the clinical data of the patient like their drug doses and corresponding changes to sizes of tumor or levels of cancer biomarkers in blood - to calibrate her or his unique response to treatment.